PDS Biotechnology Appoints Immuno-Oncology Experts Dr. Olivera Finn and Dr. Mark Frohlich to Scientific Advisory Board
May 18 2021 - 8:00AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company’s proprietary
Versamune® T-cell activating technology, today announced the
appointment of Dr. Olivera Finn and Dr. Mark Frohlich to its
Scientific Advisory Board.
Dr. Olivera Finn is a Distinguished Professor of
Immunology at the University of Pittsburgh, School of Medicine. Dr.
Finn brings over three decades of expertise in translational
research in immunology and oncology, including the discovery of the
first tumor-associated protein (antigen) recognized by T-cells,
called MUC-1. In 2016, she received the National Cancer Institute’s
Outstanding Investigator Award for her pioneering and extensive
ground-breaking research in cancer immunotherapy. Previously, Dr.
Finn served as the Director of the Cancer Immunology Program at the
University of Pittsburgh Cancer Institute and is a Distinguished
Fellow of the American Association of Immunologists. Dr. Finn
obtained a Ph.D. in Immunology, and subsequently completed her
postdoctoral fellowship at Stanford University.
Dr. Mark Frohlich is a renowned medical
oncologist and biopharma executive who brings over 20 years of
experience in developing immunotherapies for cancer. Dr. Frohlich
has extensive clinical drug development and translational research
expertise. As the Chief Medical Officer and Executive VP of R&D
at Dendreon Corporation, he led the clinical team responsible for
the development and approval of Provenge® for the treatment of
advanced prostate cancer. Provenge® was the first therapeutic
cancer vaccine to gain FDA approval. He subsequently served as
Executive VP of Portfolio Strategy at Juno Therapeutics. Dr.
Frohlich received his Doctor of Medicine degree from Harvard
Medical School and completed his internal medicine residency and
oncology fellowship at University of California San Francisco.
“We are excited to add Dr. Olivera Finn, Ph.D.
and Dr. Mark Frohlich, M.D., two world-renowned immunotherapy
experts, to our Scientific Advisory Board," commented Dr. Lauren V.
Wood, M.D., Chief Medical Officer of PDS Biotech. "These
appointments further strengthen our translational research
expertise in immuno-oncology as we prepare to progress clinical
development of PDS0102 and PDS0103 for prostate and MUC-1
associated cancers respectively, and continue to advance our lead
cancer immunotherapy PDS0101 through Phase 2 clinical testing. We
very much look forward to adding their experience and guidance to
our team of accomplished advisors.”
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy
company developing a growing pipeline of cancer immunotherapies and
infectious disease vaccines based on the Company’s proprietary
Versamune® T-cell activating technology platform. Our
Versamune®-based products overcome the limitations of current
immunotherapy by inducing in vivo, large quantities of
high-quality, highly potent polyfunctional tumor specific CD4+
helper and CD8+ killer T-cells. PDS Biotech has developed multiple
therapies, based on combinations of Versamune® and disease-specific
antigens, designed to train the immune system to better recognize
diseased cells and effectively attack and destroy them. Our
immuno-oncology product candidates are initially being studied in
combination therapy to potentially enhance efficacy without
compounding toxicity across a range of cancer types. The company’s
lead investigational cancer immunotherapy product PDS0101 is
currently in Phase 2 clinical studies in HPV-associated cancers.
PDS Biotech is also collaborating with the National Cancer
Institute to develop PDS0102 for prostate and breast cancers and to
develop PDS0103, a MUC-1 targeting immunotherapy for breast, colon,
lung and ovarian cancers. PDS Biotech has developed multiple
therapies, based on combinations of Versamune® and disease-specific
antigens, designed to train the immune system to better recognize
diseased cells and effectively attack and destroy them. To learn
more, please visit www.pdsbiotech.com or follow us on Twitter at
@PDSBiotech.
Forward Looking Statements
This communication contains forward-looking
statements (including within the meaning of Section 21E of the
United States Securities Exchange Act of 1934, as amended, and
Section 27A of the United States Securities Act of 1933, as
amended) concerning PDS Biotechnology Corporation (the “Company”)
and other matters. These statements may discuss goals, intentions
and expectations as to future plans, trends, events, results of
operations or financial condition, or otherwise, based on current
beliefs of the Company’s management, as well as assumptions made
by, and information currently available to, management.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as “may,” “will,” “should,”
“would,” “expect,” “anticipate,” “plan,” “likely,” “believe,”
“estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook”
and other similar expressions among others. Forward-looking
statements are based on current beliefs and assumptions that are
subject to risks and uncertainties and are not guarantees of future
performance. Actual results could differ materially from those
contained in any forward-looking statement as a result of various
factors, including, without limitation: the Company’s ability to
protect its intellectual property rights; the Company’s anticipated
capital requirements, including the Company’s anticipated cash
runway and the Company’s current expectations regarding its plans
for future equity financings; the Company’s dependence on
additional financing to fund its operations and complete the
development and commercialization of its product candidates, and
the risks that raising such additional capital may restrict the
Company’s operations or require the Company to relinquish rights to
the Company’s technologies or product candidates; the Company’s
limited operating history in the Company’s current line of
business, which makes it difficult to evaluate the Company’s
prospects, the Company’s business plan or the likelihood of the
Company’s successful implementation of such business plan; the
timing for the Company or its partners to initiate the planned
clinical trials for PDS0101, PDS0203 and other Versamune® based
products; the future success of such trials; the successful
implementation of the Company’s research and development programs
and collaborations, including any collaboration studies concerning
PDS0101, PDS0203 and other Versamune® based products and the
Company’s interpretation of the results and findings of such
programs and collaborations and whether such results are sufficient
to support the future success of the Company’s product candidates;
the success, timing and cost of the Company’s ongoing clinical
trials and anticipated clinical trials for the Company’s current
product candidates, including statements regarding the timing of
initiation, pace of enrollment and completion of the trials
(including our ability to fully fund our disclosed clinical trials,
which assumes no material changes to our currently projected
expenses), futility analyses, presentations at conferences and data
reported in an abstract, and receipt of interim results, which are
not necessarily indicative of the final results of the Company’s
ongoing clinical trials; the acceptance by the market of the
Company’s product candidates, if approved; the timing of and the
Company’s ability to obtain and maintain U.S. Food and Drug
Administration or other regulatory authority approval of, or other
action with respect to, the Company’s product candidates; and other
factors, including legislative, regulatory, political and economic
developments not within the Company’s control, including unforeseen
circumstances or other disruptions to normal business operations
arising from or related to COVID-19. The foregoing review of
important factors that could cause actual events to differ from
expectations should not be construed as exhaustive and should be
read in conjunction with statements that are included herein and
elsewhere, including the risk factors included in the Company’s
annual and periodic reports filed with the SEC. The forward-looking
statements are made only as of the date of this press release and,
except as required by applicable law, the Company undertakes no
obligation to revise or update any forward-looking statement, or to
make any other forward-looking statements, whether as a result of
new information, future events or otherwise.
Media & Investor Relations
Contact:
Deanne RandolphPDS BiotechPhone: +1 (908)
517-3613Email: drandolph@pdsbiotech.com
Rich CockrellCG CapitalPhone: +1 (404) 736-3838
Email: rich@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Aug 2024 to Sep 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Sep 2023 to Sep 2024